Related Experiment Video
Updated: Jul 6, 2026
13:19
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
Exploring key genes and prognostic validation of prostate cancer through transcriptome-wide association study.
Jintao Li1, Tao Tao1, Yuandong Zhang1
1Department of Urology, Affiliated Hospital of Qinghai University and Affiliated Cancer Hospital of Qinghai University, Xining, 810000, China.
Scientific Reports
|July 4, 2026
Summary
This study identifies key genes in prostate cancer (PC) progression using integrated genomic and transcriptomic data. Findings highlight asparagine synthetase (ASNS) and sulfatase modifying factor 2 (SUMF2) as potential biomarkers for PC prognosis.
Area of Science:
- Oncology
- Genetics
- Bioinformatics
Background:
- Prostate cancer (PC) is a prevalent malignancy in men globally.
- Current PC treatments face challenges in early detection and overcoming resistance.
- Identifying novel molecular targets is crucial for improving PC management.
Purpose of the Study:
- To identify key genes implicated in prostate cancer (PC) progression.
- To explore potential prognostic biomarkers for PC using integrated genomic and transcriptomic data.
Main Methods:
- Combined genome-wide association study (GWAS) with expression quantitative trait loci (eQTL) data via transcriptome-wide association study (TWAS).
- Conducted differential gene expression and survival analyses.
- Utilized the Cancer Genome Atlas Prostate Adenocarcinoma (TCGA-PRAD) dataset.
Main Results:
- Identified 46 candidate genes associated with PC.
- Upregulation of asparagine synthetase (ASNS) correlated with poor PC prognosis.
- Downregulation of sulfatase modifying factor 2 (SUMF2) was linked to adverse PC prognosis.
Conclusions:
- ASNS and SUMF2 play significant roles in prostate cancer (PC) progression.
- ASNS and SUMF2 show potential as prognostic biomarkers for PC.
- Further research into ASNS and SUMF2 could lead to improved diagnostic and therapeutic strategies for PC.
